Congress is being urged to reverse a cut to physicians’ Medicare payments; Bayer announced encouraging results on Monday of 2 phase 3 trials for its nonhormonal drug candidate meant to treat hot flashes; more students are turning to online mental health support rather than school counselors.
Congress is being urged to reverse a cut to physicians’ Medicare payments, according to Axios. As the January 19 government funding deadline approaches, doctors are putting more pressure on Congress to use the next spending package to reverse cuts that took effect January 1. There was a 3.4% cut in physician reimbursements that stemmed from Medicare’s plan to adjust the conversion factor, which is a key metric governing physician pay, and a new billing code for complex office visits; doctors argue that the cuts compound previous reimbursement cuts and will particularly harm rural physicians who work on thinner margins. Consequently, the American Medical Association (AMA) is supporting a bipartisan bill that would provide for annual increases for doctors tied to inflation. Despite this, experts consider it unlikely that Congress will agree to a more comprehensive payment change like this before the government funding deadline.
Bayer announced encouraging results on Monday of 2 phase 3 trials for elinzanetant, its nonhormonal drug candidate meant to treat hot flashes, according to Stat. Elinzanetant, a neurokinin-1 and 3 receptor antagonist, works by calming down the estrogen receptors in the brain that become hyperactive around menopause and cause hot flashes. Bayer found that the drug reduced both the frequency and intensity of hot flashes; it also was shown to improve patients’ sleep and quality of life. Bayer is behind Astellas, whose nonhormonal drug for menopausal symptom relief, fezolinetant (Veoza), won US and European approval last year. Despite this, Bayer noted that the results of a third phase 3 study are expected in the coming months, and it soon plans to submit data from all 3 trials to seek approval from health authorities.
More students are turning to online mental health support rather than school counselors, according to Bloomberg. According to a report by the Jed Foundation, 87% of teens and tweens have sought mental health information online, and 64% have used mobile health apps. Students noted that this is because of the lack of privacy while using campus mental health services and the lack of relatability as counselors are often older than them. Students are also turning to online platforms as schools are unable to meet the demand; school counseling centers are short-staffed and overwhelmed, resulting in long waiting lists that discourage students. To help schools and students alike, the US Department of Education announced grants of more than $188 million in 2023 to help increase the number of mental health professionals in schools and offer services with platforms like Closegap and Rhithm.
Industry Experts Tackle Specialty Drug Access Challenges for Employer Benefit Plans
May 2nd 2024Representatives from ICON plc and Symphony Health joined forces as AXS24 to discuss the challenges of managing high-cost specialty drugs and how they influence self-funded employer benefit plan design and employee access to specialty medications.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Specialty Pharmacists at the Forefront: Elevating Care for Rare Diseases
May 1st 2024In the US, a disease is considered rare when it affects fewer than 200,000 persons, or 1 in every 1500 individuals, with an estimated total of 25 to 30 million Americans overall living with a rare disease at any given time.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
BRCA-Like Classification May Be a Useful Biomarker for Olaparib Response in Ovarian Cancer
May 1st 2024Adding olaparib to maintenance therapy with bevacizumab was associated with significantly longer survival for patients with ovarian cancer whose tumors have a BRCA-like genomic profile, but not among those with non-BRCA-like tumors, a study found.
Read More